Pharmaceutical News

RSS

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

VIVUS terminates Luramist development, commercialization agreement with FemPharm

VIVUS, Inc. today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist™, a metered dose transdermal application of testosterone for women.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

31 Mar 2010

Social networks can spread misunderstandings about proper use of antibiotics

Misunderstandings about proper use of antibiotics have the potential to spread widely through social networks such as Twitter, according to a report in the April issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC).

31 Mar 2010

MIPA launches campaign to educate consumers save money on prescription medications

The Massachusetts Independent Pharmacists Association today announced the kickoff of a campaign aimed at educating consumers about a proposal to help save money on prescription medications. MIPA was joined by patient groups, pharmacists, and lawmakers at a Boston pharmacy, Tremont Drug, to highlight the fact that Massachusetts is the only state in the nation that bans the use of manufacturer discounts and co-pay assistance programs for the purchase of prescription drugs.

31 Mar 2010

Nation's emergency physicians warn parents about dangers of prescription drug abuse

The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.

31 Mar 2010

2010 BIO International Convention to discuss issues that impact drug discovery and development

The 2010 BIO International Convention will feature a robust health and medical program highlighting the latest scientific breakthroughs and policy and business development issues that impact drug discovery and development. Hosted by the Biotechnology Industry Organization, the Convention will be held May 3-6, 2010 in Chicago, Ill. at McCormick Place.

31 Mar 2010

New legislation will increase access to health care, says DDI

Will the newly signed health care legislation create a major shift in how pharmaceutical brand decisions are made? The bill will increase access to health insurance, but many believe the practice of medicine is already in transition, and the bill signed by President Obama will simply accelerate changes already being implemented.

31 Mar 2010

Advanced Instruments launches three new levels of Osmometer Standard Solutions

Advanced Instruments is pleased to introduce three new levels of Osmometer Standard Solutions to its product offering. The 200, 400 and 1000 mOsm/kg H20 level standards are NIST- traceable salt solutions that are packaged in 2mL ampules, 10 ampules per box. The kits are available for immediate release.

31 Mar 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

TNS signs revenue sharing agreement to launch dietary supplement products in USA

Total Nutraceutical Solutions, Inc announced today that the company has entered into a revenue sharing agreement to undertake a direct mail marketing program of a proprietary private label compound developed and manufactured by the company for joint pain and inflammation.

31 Mar 2010

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

Consumers should spring clean their medicine cabinets to prevent potential potency problems

MediNurse, now in its 25th year and the premier provider of private duty services and corporate wellness programs, reminds the public that spring cleaning is important for the medicines in your home.

31 Mar 2010

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches and widespread uptake of novel oral anticoagulants will drive the venous thromboembolism drug market to nearly double from $2.9 billion in 2008 to more than $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

31 Mar 2010

New anti-inflammatory drug shows promise for treating inflammatory disorders

Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders. But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

Pharmaceutical News

New medicines to fight diseases of particular concern to African Americans

VIVUS terminates Luramist development, commercialization agreement with FemPharm

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

Social networks can spread misunderstandings about proper use of antibiotics

MIPA launches campaign to educate consumers save money on prescription medications

Nation's emergency physicians warn parents about dangers of prescription drug abuse

2010 BIO International Convention to discuss issues that impact drug discovery and development

New legislation will increase access to health care, says DDI

Advanced Instruments launches three new levels of Osmometer Standard Solutions

Vidazorb probiotic supplements could minimize severity of IBS symptoms

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

PhRMA report: 234 medicines in development for special health care needs of children

TNS signs revenue sharing agreement to launch dietary supplement products in USA

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Consumers should spring clean their medicine cabinets to prevent potential potency problems

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

New anti-inflammatory drug shows promise for treating inflammatory disorders

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News